As per the report published by Allied Market Research, the global Erythropoietin Drugs Market was pegged at $9.24 billion in 2020, and is estimated to reach $14.41 billion by 2028, growing at a CAGR of 5.7% from 2021 to 2028.
Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/59
Rise in prevalence of cancer, HIV, anemia, and kidney diseases, surge in level of awareness about the benefits of EPO therapeutics, and commercialization for erythropoietin biosimilars drive the growth of the global erythropoietin drugs market. However, longer duration of treatment, unaffordability of therapeutics, and adverse amount of side effects hinder the market growth. On the contrary, the commercialization of darbepoetin alfa biosimilar and achieving economies of scale across developed regions are expected to open lucrative opportunities for the market players in the future.
Key Takeaways:
The darbepoetin-alfa segment is estimated to register the highest CAGR of 7.0% during the forecast period.
The segment is expected to manifest the highest CAGR of 6.5% during the forecast period.
The market across Asia-Pacific is projected to register the highest CAGR of 7.8% from 2021 to 2028.
Economic Downturn Analysis:
Increased healthcare spending in developed and developing countries facilitates better access to EPO drugs.
Government funding and insurance coverage for CKD and anemia treatments directly impact market growth.
The high cost of EPO drugs can be a barrier, but the introduction of biosimilars helps reduce treatment costs and enhances market penetration.
Erythropoietin Drugs Market Segments:
By PRODUCTS:
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
By APPLICATIONS:
Hematology
Kidney Disorder
Cancer
Others
Geography:
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Regional Analysis:
North America dominates the global erythropoietin drugs market, owing to presence of several approved and commercialized erythropoietin biosimilars. However, Asia-Pacific is characterized by presence of generic epoetin products. Asia-Pacific and LAMEA offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin drugs as compared to North America and Europe.
For Procurement Information- https://www.alliedmarketresearch.com/purchase-enquiry/59
Leading Market Players:
Johnson & Johnson
Amgen Inc.,
Roche, Hospira Inc.
Biocon
LG Life Sciences Ltd.
Teva Pharmaceutical Industries Ltd.
Intas Pharmaceuticals
Ranbaxy Laboratories Ltd.,
Celltrion, Inc.
Request Customization: https://www.alliedmarketresearch.com/request-for-customization/59
https://www.newstrail.com/three-way-stopcock-market/
https://www.newstrail.com/gastrointestinal-stents-market/
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
